Abstract
Hodgkin lymphoma (HL) is a type of lymphoma characterized by Reed-Sternberg cells and often associated with systemic symptoms. While not considered an AIDS-defining malignancy, it is one of the more common non-AIDS-defining cancers. Most cases of HIV-associated HD are associated with Epstein–Barr virus. HD in persons infected with HIV tends to involve relatively unfavorable subtypes (mixed cellularity and lymphocyte), to be relatively more aggressive, and to more frequently exhibit extranodal involvement. Many of the cases of HIV-associated HD occur in patients with only moderate immunosuppression. Also, unlike most AIDS-related non-Hodgkin lymphoma, the incidence of HIV-associated HD has not decreased with the widespread use of HAART. In the era of highly active antiretroviral therapy (HAART) the same regimens employed in HIV-negative patients with HL can be used in HIV setting with similar results.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Berenguer J, Miralles P, Ribera JM, et al. Characteristics and outcome of AIDS related Hodgkin Lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47:422–8.
Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108:3786–91.
Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis. 2009;48(5):633–9.
Carbone A, Gloghini A, Larocca LM, et al. Human immunodeficiency virus associated Hodgkin’s disease derives from post-germinal center B cells. Blood. 1999;93:2319–26.
Chimienti E, Spina M, Gastaldi R, et al. Clinical characteristics and outcome of 290 patients (pts) with Hodgkin’s disease and HIV infection (HD-HIV) in pre and HAART (highly active antiretroviral therapy) era. Ann Oncol. 2008;19:iv136, abs 168.
Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425–32.
Dal Maso L, Franceschi S, Polesel J, et al. Risk of cancer in persons with AIDS in Italy, 1985–1998. Br J Cancer. 2003;89:94–100.
Dolcetti R, Boiocchi M, Gloghini A, Carbone A. Pathogenetic and histogenetic features of HIV-associated Hodgkin’s disease. Eur J Cancer. 2001;37(10):1276–87.
Errante D, Tirelli U, Gastaldi R, et al. Combined antineoplastic and antiretroviral therapy for patients with Hodgkin’s disease and human immunodeficiency virus infection. A prospective study of 17 patients. Cancer. 1994;73:437–44.
Errante D, Gabarre J, Ridolfo AL, et al. Hodgkin’s disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann Oncol. 1999;10:189–95.
Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica. 2006;91(4):475–81.
Gloghini A, Carbone A. Why would the incidence of HIV-associated Hodgkin lymphoma increase in the setting of improved immunity? Int J Cancer. 2007;120:2753–4.
Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Ann Oncol. 2003;14:1562–9.
Hentrich M, Berger M, Wyen C, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30:4117–23.
Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008;8:22–33.
Levine AM, Li P, Cheung T, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine and dacarbazine with granulocyte-colony-stimulating factor CSF in HIV infected patients with newly diagnosed Hodgkin’s disease: a prospective, multi-institutional AIDS Clinical Trials Group study (ACTG 149). J Acquir Immune Defic Syndr. 2000;24:444–50.
Montoto S, Shaw K, Okosun J, et al. HIV status does not influence the outcome in patients with classical Hodgkin Lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine and dacarbazine in the Highly Active Antiretroviral Therapy Era. J Clin Oncol. 2012;30:4111–6.
Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27(6):884–90.
Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114(7):1306–13.
Serraino D, Pezzotti P, Dorrucci M, et al. Cancer incidence in a cohort of human immunodeficiency virus seroconveters. HIV Italian Seroconverters Study Group. Cancer. 1997;79:1004–8.
Spina M, Gabarre J, Rossi G, et al. Stanford V and concomitant HAART in 59 patients with Hodgkin’s disease and HIV infection. Blood. 2002;100:1984–8.
Spina M, Rossi G, Antinori A, et al. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV). Ann Oncol. 2008;19:iv152, abs 227.
Tirelli U, Errante D, Dolcetti R, et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol. 1995;13:1758–67.
Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodeficiency virus-related NHL in the era of HAART. Clin Infect Dis. 2003;37:1556–64.
Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica. 2007;92:191–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Spina, M., Ciancia, R., Augello, A., Berretta, M., Tirelli, U. (2014). Hodgkin Lymphoma in Patients with HIV Infection. In: Yarchoan, R. (eds) Cancers in People with HIV and AIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0859-2_17
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0859-2_17
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0858-5
Online ISBN: 978-1-4939-0859-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)